Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 for Diffuse Large B-cell Lymphoma
Golcadomide is an oral cereblon-modulating agent for the treatment of DLBCL. It exhibited rapid, deep, and sustained degradation of IKZF1 and IKZF3, preferentially accumulated in lymphoma residence tissues, and delivered robust antitumor activity. These results provide a strong rationale for continued clinical investigation of golcadomide for patients with DLBCL.
Authors
- Samuel Wood (ORCID: https://orcid.org/0009-0006-9196-5060)
- Soraya Carrancio (ORCID: https://orcid.org/0009-0004-4695-0084)
- Neil Bence (ORCID: https://orcid.org/0000-0002-6723-2880)
- Timothy Kercher (ORCID: https://orcid.org/0009-0004-9789-7439)
- Matthew Groza (ORCID: https://orcid.org/0009-0008-5642-6103)
- E. Kalashnikova (ORCID: https://orcid.org/0009-0003-9635-5227)
- Michael Angelo (ORCID: https://orcid.org/0009-0001-4310-645X)
- Andy Christoforou (ORCID: https://orcid.org/0000-0002-3933-1793)
- Gabriel C. Lander (ORCID: https://orcid.org/0000-0003-4921-1135)
- Micah Castillo (ORCID: https://orcid.org/0009-0003-5727-8118)
- Rama Krishna Narla (ORCID: https://orcid.org/0000-0001-5181-3376)
- In Sock Jang (ORCID: https://orcid.org/0000-0002-7285-7885)
- Antonia Lopez‐Girona (ORCID: https://orcid.org/0009-0009-1306-7021)
- J. Zhu (ORCID: https://orcid.org/0000-0001-5436-4262)
- Edmond R. Watson (ORCID: https://orcid.org/0000-0001-7756-4099)
- Diana Jankeel (ORCID: https://orcid.org/0009-0005-8998-3078)
- Lynda Groocock (ORCID: https://orcid.org/0000-0002-4906-932X)
- Mark Rolfe (ORCID: https://orcid.org/0009-0001-7585-2684)
- Preethi Janardhanan (ORCID: https://orcid.org/0000-0003-3719-7938)
- Celia Fontanillo (ORCID: https://orcid.org/0000-0002-3631-7881)
- Sophie X. Peng (ORCID: https://orcid.org/0009-0004-9268-8195)
- Derek Mendy (ORCID: https://orcid.org/0009-0009-7707-6832)
- Zhongying Mo (ORCID: https://orcid.org/0009-0006-3459-1365)
- Gauri Deb (ORCID: https://orcid.org/0000-0003-3559-1595)
- Daniel W. Pierce (ORCID: https://orcid.org/0000-0002-4954-3781)
- Kai Yan (ORCID: https://orcid.org/0000-0003-3262-4160)
- Kai Wang (ORCID: https://orcid.org/0000-0003-0567-3004)
- Leo A. Barnes (ORCID: https://orcid.org/0009-0005-3603-3941)
- Ryan Galasso (ORCID: https://orcid.org/0009-0004-2198-6769)
- M. Côté (ORCID: https://orcid.org/0000-0001-8693-9948)
- Geraldine Polido (ORCID: https://orcid.org/0009-0009-1135-3833)
- Álvaro Fernández-Deudero (ORCID: https://orcid.org/0009-0005-3463-8656)
Institutions
- Scripps Research Institute (US)
- Bristol-Myers Squibb (Germany) (DE)
- Bristol-Myers Squibb (United States) (US)
- MagneSensors (United States) (US)
- Healthcentric Advisors (US)
Publication Details
- Journal
- Blood Cancer Discovery
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1158/2643-3230.bcd-25-0059
- Primary Topic
- Protein Degradation and Inhibitors
- Type
- article
- Field-Weighted Citation Impact
- 0.00